Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2Phase EARLY_PHASE1 1

Status

Completed 35Unknown 19Terminated 14Recruiting 13Not yet recruiting 9Active not recruiting 9Withdrawn 6Suspended 1

Sponsor Class

OTHER 6NIH 1

Study Type

Interventional 6

Sponsor

Cancer Type

Breast 6Gynecologic 2Sarcoma 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Breast Neoplasms 5Ovarian Neoplasms 2Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Brain Neoplasms 1Advanced Breast Cancer 1

Interventions

Radiotherapy 91pembrolizumab 88Cyclophosphamide 84Gemcitabine 70Cisplatin 70Magnetic Resonance Spectroscopy 65Carboplatin 60Radiosurgery 55Paclitaxel 55Nivolumab 48Dexamethasone 45Bevacizumab 42Biopsy 41Fluorouracil 39durvalumab 37Surveys and Questionnaires 36Docetaxel 36fludarabine 35Doxorubicin 35Radiation 33Oxaliplatin 33Capecitabine 33Rituximab 32fludarabine phosphate 31Leucovorin 31Cytarabine 30Melphalan 29Etoposide 28Pemetrexed 27Irinotecan 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Withdrawn × OTHER × eribulin × Clear all
NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

OHSU Knight Cancer Institute

Phase EARLY_PHASE1 Withdrawn
BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT04826016 2023-03-20

POLTER

MedSIR

Phase 1/2 Withdrawn
Breast

Advanced Breast Cancer

NCT03637868 2020-05-06

ERIBRAIN

Institut Paoli-Calmettes

Phase 2 Withdrawn
BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT03032614 2017-10-10

Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients

The University of Texas Health Science Center at San Antonio

Phase 2 Withdrawn
BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

NCT02215876 2016-04-15

Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Eribulin Chemotherapy (ACE) in Operable HER2-negative Breast Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Withdrawn
Breast

Breast Neoplasms

NCT02396433 2015-08-25

Combination of Carboplatin, Eribulin Mesylate, and E7449 in BRCA-Related Cancers

The University of Texas Health Science Center at San Antonio

Phase 1/2 Withdrawn
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡